Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Isogenica to research with GE Healthcare

May 15, 2006 | A version of this story appeared in Volume 84, Issue 20

Isogenica and GE Healthcare have formed a collaboration for the discovery of novel in vivo diagnostic and medical imaging compounds. Isogenica will use its CIS display technology to select peptide ligands for two undisclosed disease targets that will be identified by GE. According to the firms, the CIS technology rapidly identifies peptides that bind to any given molecular target. The technology can also be used to enhance the in vivo performance of peptide therapeutic and diagnostic products. GE will have an option to advance to clinical development any imaging agent resulting from the collaboration.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.